Shanghai University of

Company snapshot

The Shanghai University of Chinese Medicine, officially "Shanghai University of Traditional Chinese Medicine", also called the "Shanghai Academy of Traditional Chinese Medicine", is a leading medical institution in [Shanghai](en.wikipedia.org/wiki/Shanghai), China. With a history tracible to 1916, the school is one of the earliest four Chinese medical colleges in China. In 2026, Shanghai Universit

• 24 active pipeline program(s) linked via ClinicalTrials.gov.
• 24 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shanghai University of. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Shanghai University of.

1. Jun 8, 2026 Clinical update

   YZJ-1139 tablets — Phase 1

2. Jun 8, 2026 Clinical update

   TQB2825 Injection (Subcutaneous Injection) — Phase 1

3. Jun 8, 2026 Clinical update

   Sodium Thiosulfate Injection — Phase 3

4. Jun 8, 2026 Clinical update

   SCT-001 CAR-T cells — Phase 1

5. Jun 8, 2026 Clinical update

   Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo — Phase 1

View all clinical trial activity →

• What is Shanghai University of?

  Shanghai University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Alzheimer Disease, Pulmonary Fibrosis, RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, Chemotherapy, Adjuvant, Neoplasms. NovaPharmaNews links 24 clinical program(s), 0 drug profi

• Is Shanghai University of publicly traded?

  Shanghai University of appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shanghai University of develop or market?

  We link 33 drug profile(s) where Shanghai University of is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shanghai-university-of-traditional-chinese-medicine#company-drugs.

• What are the latest developments for Shanghai University of?

  In the last 12 months our linked public records show 24 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Shanghai University of focus on?

  Shanghai University of focuses on Alzheimer Disease, Pulmonary Fibrosis, RESPIRATORY SYNCYTIAL VIRUS INFECTIONS based on our analysis of their pipeline programs and drug development activities.